All
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia Treatment
October 22nd 2024As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting the effectiveness of that therapy.
Compliance Gap: Why Labeling and Instructions for Use Documents Need to Be a Single Process
October 18th 2024Rather than relying on a myriad of different systems, the author proposes that a cloud-based solution can control and coordinate everything, allowing manufacturers to deftly respond when changes in labeling requirements arise.
AAPS PharmSci 360 2024: The Future of Bioanalysis
October 18th 2024Xiao-Yan Cai, PhD, co-founder and CEO of Accurant Biotech, discussed collaborative efforts that must be undertaken between companies, and across scientific disciplines, to work together on continuing to develop medicines to save lives.
CPHI Milan 2024: Pharma Industry Growth and Investment
October 11th 2024Pharmaceutical Technology Europe spoke with John McQuaid, president and managing director at Almac Pharma Services, at CPHI Milan 2024, held October 8–10, in Milan, Italy, about how the pharmaceutical industry is growing and what might drive investment in the future.
CPHI Milan 2024: Heparin and Heparinoids in Pharmaceuticals
October 10th 2024Pharmaceutical Technology Europe sat down with Joan Bassa, Human Health Business Unit Director at Bioiberica, to talk about the history of heparin, its uses in pharmaceuticals, and what heparinoids have to offer the industry.
AAPS PharmSci 360 2024: Predictive Models for Poorly Soluble Drugs
October 10th 2024Pharmaceutical Technology sat down with Niloufar Salehi, advisor at Eli Lilly & Company, to talk about the session she is moderating at AAPS PharmSci 360 2024, Symposium: An Accelerated Development of Poorly Soluble Drugs Using Predictive Tool.
CPHI Milan 2024: Evolution of Coating Design
October 9th 2024Pharmaceutical Technology Europe spoke with Ali Rajabi-Siahboomi, vice president and chief innovation officer at Colorcon, about the evolution of coating design and how it has impacted investment, as well as innovations in packaging for oral solid dosage products.